|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyle P and Langman J: ABC of colorectal
cancer: Epidemiology. BMJ. 321:805–808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lech G, Slotwiński R, Słodkowski M and
Krasnodębski IW: Colorectal cancer tumour markers and biomarkers:
Recent therapeutic advances. World J Gastroenterol. 22:1745–1755.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Milner J and Medcalf E: Cotranslation of
activated mutant p53 with wild type drives the wild-type p53
protein into the mutant conformation. Cell. 65:765–774. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milner J, Medcalf EA and Cook AC: Tumor
suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol
Cell Biol. 11:12–19. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hermeking H: MicroRNAs in the p53 network:
Micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song
JS, Tang LH, Levine AJ and Feng Z: Negative regulation of tumor
suppressor p53 by microRNA miR-504. Mol Cell. 38:689–699. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng Z, Zhang C, Wu R and Hu W: Tumor
suppressor p53 meets microRNAs. J Mol Cell Biol. 3:44–50. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SY, Lee JH, Ha M, Nam JW and Kim VN:
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat
Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamakuchi M and Lowenstein CJ: MiR-34,
SIRT1 and p53: The feedback loop. Cell Cycle. 8:712–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song B, Wang Y, Kudo K, Gavin EJ, Xi Y and
Ju J: miR-192 Regulates dihydrofolate reductase and cellular
proliferation through the p53-microRNA circuit. Clin Cancer Res.
14:8080–8086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pichiorri F, Suh SS, Rocci A, De Luca L,
Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder
H, et al: Downregulation of p53-inducible microRNAs 192, 194, and
215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma
development. Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manfe V, Biskup E, Rosbjerg A, Kamstrup M,
Skov AG, Lerche CM, Lauenborg BT, Odum N and Gniadecki R: miR-122
regulates p53/Akt signalling and the chemotherapy-induced apoptosis
in cutaneous T-cell lymphoma. PloS One. 7:e295412012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stahlhut C and Slack FJ: MicroRNAs and the
cancer phenotype: Profiling, signatures and clinical implications.
Genome Med. 5:1112013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang L, Lai YK, Zhang J, Wang H, Lin MC,
He ML and Kung HF: Targeting S100P inhibits colon cancer growth and
metastasis by Lentivirus-mediated RNA interference and proteomic
analysis. Mol Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Lin MC, Yao H, Wang H, Zhang AQ,
Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF:
Lentivirus-mediated RNA interference targeting enhancer of zeste
homolog 2 inhibits hepatocellular carcinoma growth through
down-regulation of stathmin. Hepatology. 46:200–208. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou G, Wang J, Zhao M, Xie TX, Tanaka N,
Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, et al:
Gain-of-function mutant p53 promotes cell growth and cancer cell
metabolism via inhibition of AMPK activation. Mol Cell. 54:960–974.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lenfert E, Maenz C, Heinlein C, Jannasch
K, Schumacher U, Pantel K, Tolstonog GV, Deppert W and Wegwitz F:
Mutant p53 promotes epithelial-mesenchymal plasticity and enhances
metastasis in mammary carcinomas of WAP-T mice. Int J Cancer.
136:E521–E533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ji L, Xu J, Liu J, Amjad A, Zhang K, Liu
Q, Zhou L, Xiao J and Li X: Mutant p53 promotes tumor cell
malignancy by both positive and negative regulation of the
transforming growth factor β (TGF-β) pathway. J Biol Chem.
290:11729–11740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arjonen A, Kaukonen R, Mattila E, Rouhi P,
Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, et al:
Mutant p53-associated myosin-X upregulation promotes breast cancer
invasion and metastasis. J Clin Invest. 124:1069–1082. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bossi G, Marampon F, Maor-Aloni R, Zani B,
Rotter V, Oren M, Strano S, Blandino G and Sacchi A: Conditional
RNA interference in vivo to study mutant p53 oncogenic gain of
function on tumor malignancy. Cell Cycle. 7:1870–1879. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: Reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI
|
|
35
|
Khoo KH, Verma CS and Lane DP: Drugging
the p53 pathway: Understanding the route to clinical efficacy. Nat
Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu H, Mao Q, Lin Y, Yang K and Xie L: RNA
interference targeting mutant p53 inhibits growth and induces
apoptosis in DU145 human prostate cancer cells. Med Oncol.
28:(Suppl 1). S381–S387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ and
Xie LP: Silencing of mutant p53 by siRNA induces cell cycle arrest
and apoptosis in human bladder cancer cells. World J Surg Oncol.
11:222013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cohen M, Wuillemin C, Irion O and Bischof
P: Regulation of MMP-9 by p53 in first trimester cytotrophoblastic
cells. Hum Reprod. 23:2273–2281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Martelli M, Campana A and Bischof P:
Secretion of matrix metalloproteinases by human endometrial cells
in vitro. J Reprod Fertil. 98:67–76. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu J, Zhan M, Hannay JA, Das P, Bolshakov
SV, Kotilingam D, Yu D, Lazar AF, Pollock RE and Lev D: Wild-type
p53 inhibits nuclear factor-kappaB-induced matrix
metalloproteinase-9 promoter activation: Implications for soft
tissue sarcoma growth and metastasis. Mol Cancer Res. 4:803–810.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nawrocki-Raby B, Gilles C, Polette M,
Martinella-Catusse C, Bonnet N, Puchelle E, Foidart JM, Van Roy F
and Birembaut P: E-cadherin mediates MMP down-regulation in highly
invasive bronchial tumor cells. Am J Pathol. 163:653–661. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chaw SY, Majeed AA, Dalley AJ, Chan A,
Stein S and Farah CS: Epithelial to mesenchymal transition (EMT)
biomarkers-E-cadherin, beta-catenin, APC and Vimentin-in oral
squamous cell carcinogenesis and transformation. Oral Oncol.
48:997–1006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roger L, Jullien L, Gire V and Roux P:
Gain of oncogenic function of p53 mutants regulates E-cadherin
expression uncoupled from cell invasion in colon cancer cells. J
Cell Sci. 123:1295–1305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dong P, Karaayvaz M, Jia N, Kaneuchi M,
Hamada J, Watari H, Sudo S, Ju J and Sakuragi N: Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene. 32:3286–3295. 2013.
View Article : Google Scholar : PubMed/NCBI
|
